Výzkumná studie, která má zjistit, jak moc CagriSema snižuje hladinu cukru v krvi a tělesnou hmotnost ve srovnání s placebem u lidí s diabetem 2. typu léčených dietou a cvičením (REIMAGINE 1)
Účinnost a bezpečnost současně podávaného cagrilintidu a semaglutidu (CagriSema) s.c. v dávkách 2,4 mg/2,4 mg a 1,0 mg/1,0 mg jednou týdně versus placebo u účastníků s diabetem 2. typu nedostatečně kontrolovaným dietou a cvičením
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Bergamo, Itálie, 24127
- Azienda Ospedaliera Papa Giovanni XXIII
-
Catanzaro, Itálie, 88100
- Policlinico Mater Domini Università di Catanzaro
-
Milan, Itálie, 20132
- IRCCS Ospedale San Raffaele Milano
-
Roma, Itálie, 00161
- Azienda Ospealiero Universitaria Policlinico Umberto I
-
-
-
-
-
Budapest, Maďarsko, 1032
- Szent Margit Rendelőintézet Nonprofit Kft.
-
Budapest, Maďarsko, 1102
- PVN Kutató Kft.
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Maďarsko, 4025
- Belinus Bt.
-
-
Szabolcs-Szatmar Varmegye
-
Nyíregyháza, Szabolcs-Szatmar Varmegye, Maďarsko, 4405
- Borbánya Praxis E.Ü. Kft.
-
-
-
-
-
Bialystok, Polsko, 15-351
- Osteo-Medic s.c. A. Racewicz, J. Supronik
-
Bialystok, Polsko, 15-797
- Renew Clinic Sp. z o.o.
-
Lodz, Polsko, 90-338
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
-
Warsaw, Polsko, 02-507
- Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
-
Warsaw, Polsko, 00-710
- NBR Polska Tomasz Klodawski
-
Zamość, Polsko, 22-400
- Velocity Nova Sp. z o.o.
-
-
Podkarpackie Voivodeship
-
Rzeszów, Podkarpackie Voivodeship, Polsko, 35-055
- Centrum Medyczne Medyk Sp. z o.o.
-
-
-
-
-
Al Ahsa, Saudská arábie, 36428
- King Abdulaziz Hospital-Al Ahsa-National Guard
-
Jeddah, Saudská arábie, 21423
- National Guard Hospital - Jeddah
-
Riyadh, Saudská arábie, 11525
- King Fahad Medical City
-
Riyadh, Saudská arábie, 12372
- King Khaled University Hospital,King Saud Univ. Med. City
-
Riyadh, Saudská arábie, 12769
- King Salman Bin Abdulaziz Hospital
-
-
-
-
California
-
Huntington Park, California, Spojené státy, 90255
- Nat Res Inst Huntington Park
-
Northridge, California, Spojené státy, 91325
- Valley Clinical Trials, Inc.
-
Santa Ana, California, Spojené státy, 92701
- Southern California Dermatology
-
-
Florida
-
Hollywood, Florida, Spojené státy, 33024
- Encore Medical Research LLC
-
Orlando, Florida, Spojené státy, 32819
- Headlands Research Orlando
-
Weston, Florida, Spojené státy, 33331
- Encore Medical Research of Weston
-
-
Kansas
-
Newton, Kansas, Spojené státy, 67114
- Alliance for Multispec Res
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02115
- Brigham & Women's Hospital
-
-
Michigan
-
Troy, Michigan, Spojené státy, 48098
- Arcturus HC PLC Troy Med Res
-
-
New York
-
West Seneca, New York, Spojené státy, 14224
- Southgate Medical Group, LLP
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97210
- Summit Research Network Oregon Inc.
-
-
Tennessee
-
Kingsport, Tennessee, Spojené státy, 37660
- Holston Medical Group
-
-
Texas
-
Amarillo, Texas, Spojené státy, 79124
- Amarillo Medical Specialists
-
Austin, Texas, Spojené státy, 78704
- Elligo Clin Res Centre
-
Brownsville, Texas, Spojené státy, 78526
- Headlands Research Brownsville
-
Dallas, Texas, Spojené státy, 75230
- Velocity Clinical Res-Dallas
-
San Antonio, Texas, Spojené státy, 78233
- Northeast Clinical Research of San Antonio
-
Shavano Park, Texas, Spojené státy, 78231
- Consano Clinical Research, LLC
-
Sugar Land, Texas, Spojené státy, 77479
- Sugar Lakes Family Practice PA
-
Weslaco, Texas, Spojené státy, 78596
- Valley Diab. & Endo Comp Ctr
-
-
Virginia
-
Newport News, Virginia, Spojené státy, 23606
- TPMG Clinical Research
-
-
-
-
-
Belgrade, Srbsko, 11080
- Clinical Hospital Center Bezanijska Kosa
-
Belgrade, Srbsko, 11080
- Clinical Hospital Centre Zemun
-
Belgrade, Srbsko, 11000
- CHC Zvezdara, Clinical department for endocrinology
-
Zaječar, Srbsko, 19000
- Policlinic for diabetes
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Čína, 100853
- Chinese People's Liberation Army General Hospital-Endocrinology
-
-
Jiangsu
-
Nanjing, Jiangsu, Čína, 210011
- The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
-
Zhenjiang, Jiangsu, Čína, 212001
- The Affiliated Hospital of Jiangsu University-Endocrinology
-
-
Shandong
-
Ji'Nan, Shandong, Čína, 250000
- Jinan Central Hospital
-
Jinan, Shandong, Čína, 250000
- Jinan Central Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Male or female
- Age 18 years or above at the time of signing the informed consent
- Diagnosed with type 2 diabetes >=30 days before screening
- HbA1c 7.0-9.5 percent (53-80 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening
- Body mass index (BMI) >=23 kilograms per square meter (kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening
Exclusion Criteria:
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method
- Renal impairment with estimated Glomerular Filtration Rate less than 30 milliliter per minute per 1.73 square meter (ml/min/1.73 m^2) as determined by central laboratory at screening
- Treatment with any medication for the indication of diabetes or obesity within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
- History of use of any injectable therapy for diabetes or obesity. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Aktivní komparátor: CagriSema Dose 2
Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks. |
Participants will receive once-weekly cagrilintide subcutaneously. Participants will receive once-weekly semaglutide subcutaneously. |
|
Komparátor placeba: Placebo Dose 2
Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 2 for 40 weeks. |
Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously. |
|
Aktivní komparátor: Cagrisema Dose 1
Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks. |
Participants will receive once-weekly cagrilintide subcutaneously. Participants will receive once-weekly semaglutide subcutaneously. |
|
Komparátor placeba: Placebo Dose 1
Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 1 for 40 weeks. |
Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in glycated haemoglobin (HbA1c)
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as percentage (%)-points. |
From baseline (week 0) to end of treatment (week 40)
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Relative change in body weight
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured in %. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve greater than or equal to (>=) 10% body weight reduction
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=15% body weight reduction
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])
Časové okno: At end of treatment (week 40)
|
Measured as count of participants. |
At end of treatment (week 40)
|
|
Number of participants who achieve HbA1c target values of less than or equal to (<=) 6.5% (<= 48 mmol/mol)
Časové okno: At end of treatment (week 40)
|
Measured as count of participants. |
At end of treatment (week 40)
|
|
Change in Fasting Plasma Glucose (FPG)
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured in millimoles per liter (mmol/L). |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=5% body weight reduction
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=20% body weight reduction
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in waist circumference
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured in centimeters (cm). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in systolic blood pressure (SBP)
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured in millimeters of mercury (mmHg). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in diastolic blood pressure (DBP)
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured in mmHg. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in high sensitivity C-reactive protein (hsCRP)
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Total cholesterol
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Triglycerides
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Free fatty acids
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Non-HDL cholesterol
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve type 2 diabetes (T2D) remission (HbA1c <6.5% and no antidiabetic medication)
Časové okno: At end of study (week 52)
|
Measured as count of participants. |
At end of study (week 52)
|
|
Ratio to baseline in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo)
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in experienced level of energy as measured by the SF-36v2 Health Survey Acute (SF-36v2) Vitality score
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The vitality score range is from 25.6 to 69.1. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in SF-36v2 score: Physical Component Summary score
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for physical component summary is 6.1 to 79.7. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in SF-36v2 score: Mental Component Summary score
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for mental component summary score is -3.8 to 78.7. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. DTSQs measures treatment satisfaction and diabetes-specific quality of life. The measure consists of 8 items yielding 1 global score and 2 single item scores. Higher scores on the global score indicate greater satisfaction with treatment. Lower scores on the single-item scores indicate BG levels closer to the ideal, while higher scores indicate problems. Single-item scores (score range): Perceived frequency of hyperglycaemia (0-6), Perceived frequency of hypoglycaemia (0-6). Global score (score range): Total Treatment Satisfaction (0-36). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in leptin
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured in nanograms per milliliter (ng/mL). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in soluble leptin receptor
Časové okno: From baseline (week 0) to end of treatment (week 40)
|
Measured in ng/mL. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of Treatment Emergent Adverse Events (TEAEs)
Časové okno: From baseline (week 0) to end of treatment +7 weeks (week 47)
|
Measured as count of events. |
From baseline (week 0) to end of treatment +7 weeks (week 47)
|
|
Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose (BG) meter
Časové okno: From baseline (week 0) to end of treatment +7 weeks (week 47)
|
Measured as count of episodes. |
From baseline (week 0) to end of treatment +7 weeks (week 47)
|
|
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Časové okno: From baseline (week 0) to end of treatment + 7 weeks (week 47)
|
Measured as count of episodes. |
From baseline (week 0) to end of treatment + 7 weeks (week 47)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- NN9388-4895
- 2022-502677-42 (Jiný identifikátor: European Medical Agency (EMA))
- U1111-1283-0404 (Jiný identifikátor: World Health Organization (WHO))
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .